Fact based stock research
Jointown Pharmaceutical (SHSE:600998)

CNE100000W45

Jointown Pharmaceutical stock research in summary

Jointown Pharmaceutical shares have a market-typical stock price level. They are safely financed, show above average growth and are good value. We recommend evaluating whether the future of the company Jointown Pharmaceutical is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.

Latest Obermatt Ranks


Value Rank	63
Growth Rank	66
Safety Rank	90
Combined Rank	93

Country	China
Industry	Health Care Distributors
Index	SSE Composite
Size class	XX-Large

May 15, 2020. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

Google: Jointown Pharmaceutical

News	Videos
Wikipedia about Jointown Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Research History: Jointown Pharmaceutical

RESEARCH HISTORY	2017	2018	2019	2020
VALUE
VALUE	52	74	73	63
GROWTH
GROWTH	93	46	61	66
SAFETY
SAFETY	58	62	59	90
COMBINED
COMBINED	80	69	83	93

Last update of Combined Rank: 15-May-2020. Financial reporting date used for calculating ranks: 31-Mar-2020. Stock research history is based on the Obermatt Method. The higher the rank, the better Jointown Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2017	2018	2019	2020
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	87	86	91	82
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	35	54	67	63
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	60	68	78	57
DIVIDEND YIELD
DIVIDEND YIELD	1	42	28	34
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	52	74	73	63

Last update of Value Rank: 15-May-2020. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Jointown Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2017	2018	2019	2020
REVENUE GROWTH
REVENUE GROWTH	93	42	70	69
PROFIT GROWTH
PROFIT GROWTH	63	80	56	66
STOCK RETURNS
STOCK RETURNS	60	26	40	57
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	93	46	61	66

Last update of Growth Rank: 31-Mar-2020. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Jointown Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2017	2018	2019	2020
LEVERAGE
LEVERAGE	30	38	30	41
REFINANCING
REFINANCING	87	96	98	98
LIQUIDITY
LIQUIDITY	13	38	41	66
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	58	62	59	90

Last update of Safety Rank: 8-May-2020. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Jointown Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Jointown Pharmaceutical from May 15, 2020.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.